Published August 14, 2019 | Version v1
Journal article Open

A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding

  • 1. University of Gothenburg
  • 2. KTH Royal Institute of Technology
  • 3. AstraZeneca
  • 4. Chalmers University of Technology

Description

The development of a fluorescent LCK inhibitor that exhibits favourable solvatochromic properties upon binding the kinase is described. Fluorescent properties were realised through the inclusion of a prodan‐derived fluorophore into the pharmacophore of an ATP‐competitive kinase inhibitor. Fluorescence titration experiments demonstrate the solvatochromic properties of the inhibitor, in which dramatic increase in emission intensity and hypsochromic shift in emission maxima are clearly observed upon binding LCK. Microscopy experiments in cellular contexts together with flow cytometry show that the fluorescence intensity of the inhibitor correlates with the LCK concentration. Furthermore, multiphoton microscopy experiments demonstrate both the rapid cellular uptake of the inhibitor and that the two‐photon cross section of the inhibitor is amenable for excitation at 700 nm.

Notes

The authors acknowledge financial support from the European Unions Horizon 2020 programme (grant no 745626); the Swedish Research Council (grant no 2016-03601 and 2015-05268) and Olle Engkvist Byggmstare Foundation.

Files

Fleming_et_al-2019-ACIE.pdf

Files (1.4 MB)

Name Size Download all
md5:e74bb9d909e4a3c3f6269362d8a47025
1.4 MB Preview Download

Additional details

Funding

European Commission
PCAGED-KI - Photocaged Kinase Inhibitors as Molecular Tools for Investigating Neurodegenerative Diseases 745626